Surrozen Inc
NASDAQ:SRZN

Watchlist Manager
Surrozen Inc Logo
Surrozen Inc
NASDAQ:SRZN
Watchlist
Price: 12.23 USD 15.76% Market Closed
Market Cap: 39.7m USD
Have any thoughts about
Surrozen Inc?
Write Note

Surrozen Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Surrozen Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Surrozen Inc
NASDAQ:SRZN
Net Income (Common)
-$43m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Surrozen Inc
Glance View

Market Cap
39.7m USD
Industry
Biotechnology

Surrozen, Inc. is a preclinical stage biotechnology company, which engages in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company is headquartered in South San Francisco, California and currently employs 83 full-time employees. The company went IPO on 2020-11-23. The firm is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The firm's product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in the activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancer Engineered for Tissue Specificity (SWEETS), enable to selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body’s response to naturally occurring Wnt proteins. The firm's two lead product candidates include SZN-1326 and SZN-043.

SRZN Intrinsic Value
16.89 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Surrozen Inc's Net Income (Common)?
Net Income (Common)
-43m USD

Based on the financial report for Dec 31, 2023, Surrozen Inc's Net Income (Common) amounts to -43m USD.

What is Surrozen Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-10%

Over the last year, the Net Income (Common) growth was -20%. The average annual Net Income (Common) growth rates for Surrozen Inc have been -10% over the past three years .

Back to Top